Stock MVP MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Medical Developments International Limited

Equities

MVP

AU000000MVP2

Pharmaceuticals

Market Closed - Australian S.E.
Other stock markets
 02:10:44 2024-04-26 am EDT 		5-day change 1st Jan Change
0.54 AUD -3.57% Intraday chart for Medical Developments International Limited -4.42% -28.95%
Feb. 29 Transcript : Medical Developments International Limited, H1 2024 Earnings Call, Feb 29, 2024
Feb. 28 Medical Developments International Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 347.2 458.1 320.7 104.1 66.89 46.6 - -
Enterprise Value (EV) 1 321.8 445.9 287.5 84.06 66.89 32.7 38.6 39.1
P/E ratio 331 x 1,203 x -24.5 x - -11.6 x -3.31 x -7.3 x -20.8 x
Yield 0.75% 0.29% - - - - - -
Capitalization / Revenue 16.2 x 19.4 x 12.7 x 4.65 x 2.07 x 1.35 x 1.13 x 0.97 x
EV / Revenue 15.1 x 18.9 x 11.4 x 3.76 x 2.07 x 0.95 x 0.94 x 0.82 x
EV / EBITDA 93.5 x 165 x -129 x -7.17 x -4.42 x -2.4 x -8.58 x 78.2 x
EV / FCF 16.3 x -338 x -28.4 x -7.02 x - -4.19 x -8.98 x -65.2 x
FCF Yield 6.15% -0.3% -3.53% -14.2% - -23.8% -11.1% -1.53%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 65,517 65,623 71,265 71,305 86,305 86,305 - -
Reference price 2 5.300 6.980 4.500 1.460 0.7750 0.5400 0.5400 0.5400
Announcement Date 8/20/19 8/20/20 8/24/21 8/25/22 8/31/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 21.38 23.64 25.27 22.37 32.34 34.5 41.1 47.8
EBITDA 1 3.441 2.695 -2.223 -11.72 -15.13 -13.6 -4.5 0.5
EBIT 1 1.174 0.098 -5.972 -14.67 -18.25 -11.5 -7.5 -2.5
Operating Margin 5.49% 0.41% -23.63% -65.58% -56.42% -33.33% -18.25% -5.23%
Earnings before Tax (EBT) 1 1.551 0.321 -14.98 - - -16.4 -7.4 -2.6
Net income 1 1.038 0.379 -12.56 -12.41 -5.609 -14 -6.4 -2.3
Net margin 4.85% 1.6% -49.72% -55.47% -17.35% -40.58% -15.57% -4.81%
EPS 2 0.0160 0.005800 -0.1835 - -0.0666 -0.1630 -0.0740 -0.0260
Free Cash Flow 1 19.78 -1.32 -10.14 -11.98 - -7.8 -4.3 -0.6
FCF margin 92.53% -5.58% -40.11% -53.54% - -22.61% -10.46% -1.26%
FCF Conversion (EBITDA) 574.95% - - - - - - -
FCF Conversion (Net income) 1,905.97% - - - - - - -
Dividend per Share 0.0400 0.0200 - - - - - -
Announcement Date 8/20/19 8/20/20 8/24/21 8/25/22 8/31/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: Juni 2020 S1 2020 S2 2021 S1 2021 S2 2023 S1 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 10.9 12.74 12.57 12.7 - - 19.5 19.4 21.7
EBITDA 1 1.503 1.192 0.285 -2.508 - - -2.2 -2.8 -1.7
EBIT 1 0.215 -0.117 -1.311 -4.661 - - -3.7 -4.4 -3.2
Operating Margin 1.97% -0.92% -10.43% -36.71% - - -18.97% -22.68% -14.75%
Earnings before Tax (EBT) 1 0.373 -0.052 - - - - -3.6 -4.3 -3.2
Net income 1 0.24 0.139 -1.137 -11.43 2.658 -10.94 -3.1 -3.7 -2.7
Net margin 2.2% 1.09% -9.04% -90% - - -15.9% -19.07% -12.44%
EPS 2 - 0.002200 - - - - -0.0360 -0.0420 -0.0310
Dividend per Share - - - - - - - - -
Announcement Date 2/18/20 8/20/20 2/25/21 8/24/21 2/23/23 2/28/24 - - -
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: Juni 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 25.4 12.2 33.2 20.1 - 13.9 8 7.5
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 19.8 -1.32 -10.1 -12 - -7.8 -4.3 -0.6
ROE (net income / shareholders' equity) 3.16% 0.86% -8.45% -19.8% -8.09% -18% -9% -4%
ROA (Net income/ Total Assets) 1.55% 0.45% -5.1% -12.9% -5.8% - - -
Assets 1 67.18 84.78 246.5 96.2 96.77 - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - 0 -0.1300 -0.1500 - - - -
Capex 1 1.49 1.49 1.25 1.2 1.78 1.7 2.1 2.2
Capex / Sales 6.95% 6.31% 4.93% 5.36% 5.52% 4.93% 5.11% 4.6%
Announcement Date 8/20/19 8/20/20 8/24/21 8/25/22 8/31/23 - - -
1AUD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Medical Developments International Limited

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED Stock Medical Developments International Limited
-28.95% 30.39M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MVP Stock
  4. Financials Medical Developments International Limited